2.84
2.16%
0.06
Dopo l'orario di chiusura:
2.85
0.01
+0.35%
Precedente Chiudi:
$2.78
Aprire:
$2.82
Volume 24 ore:
118.71K
Relative Volume:
1.67
Capitalizzazione di mercato:
$3.97M
Reddito:
-
Utile/perdita netta:
$-12.30M
Rapporto P/E:
-0.4416
EPS:
-6.4313
Flusso di cassa netto:
$-11.13M
1 W Prestazione:
-16.10%
1M Prestazione:
-17.20%
6M Prestazione:
-63.31%
1 anno Prestazione:
-67.07%
Palisade Bio Inc Stock (PALI) Company Profile
Nome
Palisade Bio Inc
Settore
Industria
Telefono
(858) 704-4900
Indirizzo
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Palisade Bio Inc Borsa (PALI) Ultime notizie
Palisade Bio (NASDAQ:PALI) and Allogene Therapeutics (NASDAQ:ALLO) Critical Survey - Defense World
Palisade Bio advances novel IBD treatment PALI-2108 - Investing.com
Palisade Bio advances novel IBD treatment PALI-2108 By Investing.com - Investing.com UK
HYCU® Recognized as CRN 2024 Product of the Year Finalist - The Manila Times
Palisade Bio Announces Positive Data from Two Ex Vivo - GlobeNewswire
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan
PALI stock touches 52-week low at $3.09 amid market fluctuations - Investing.com
Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral - MedCity News
Palisade Bio Announces Abstract Accepted for Presentation - GlobeNewswire
Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting - The Manila Times
Sutro Biopharma (NASDAQ:STRO) & Palisade Bio (NASDAQ:PALI) Head-To-Head Contrast - Defense World
Meta Platforms (NASDAQ:META) Shares Up 0.6% Following Analyst Upgrade - Defense World
Palisade Bio receives Health Canada nod for UC drug trial By Investing.com - Investing.com Australia
Palisade Bio receives Health Canada nod for UC drug trial - Investing.com
Palisade Bio Cleared by Health Canada to Commence Phase 1 - GlobeNewswire
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) - Yahoo Finance
Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - The Manila Times
Palisade Bio, Inc. (NASDAQ:PALI) Shares Sold by Armistice Capital LLC - Defense World
Palisade Bio inks new deal with CEO Finley; terms disclosed By Investing.com - Investing.com Canada
Palisade Bio inks new deal with CEO Finley; terms disclosed - Investing.com India
Palisade Bio CEO Finley’s Revised Employment and Compensation Deal - TipRanks
Palisade submits CTA for PDE4 inhibitor prodrug for ulcerative colitis - BioWorld Online
PALI stock touches 52-week low at $3.3 amid market fluctuations - Investing.com UK
PALIPalisade Bio, Inc. Latest Stock News & Market Updates - StockTitan
Palisade Bio Provides Update on Progress Toward Launch of - GlobeNewswire
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan
Klea Holding Evaluates Generous Takeover Offer - TipRanks
The growth track for Kura Oncology Inc (KURA) has changed recently - SETE News
Potential Price Increase for Kulicke & Soffa Industries, Inc. (KLIC) After Recent Insider Activity - Knox Daily
Big Changes At Disney Animation: Jennifer Lee Steps Down And Jared Bush Steps In - mxdwn.com
116,268 Shares in Proficient Auto Logistics, Inc. (NASDAQ:PAL) Purchased by First Eagle Investment Management LLC - MarketBeat
Angelina Jolie overwhelmed by ‘beautiful feeling’ of motherhood - FemaleFirst
Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga
Palisade Bio (NASDAQ:PALI) Stock Quotes, Forecast and News Summary - Benzinga
Proficient Auto Logistics (NASDAQ:PAL) Earns "Outperform" Rating from Barrington Research - MarketBeat
Jared Bush Taking Over Jennifer Lee’s Role As Walt Disney Animation Studios Chief Creative Officer - What's On Disney Plus
Alaska Air completes acquisition of Hawaiian Airlines - The Seattle Times
Bokf Na Has $58,000 Stock Position in Haleon plc (NYSE:HLN) - Defense World
CERo Therapeutics Hldgs (NASDAQ:CERO) Stock Quotes, Forecast and News Summary - Benzinga
Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies - StockTitan
Palisade Bio Launches New Corporate Branding and Reiterates - GlobeNewswire
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga
Why Palisade Bio Stock Is Soaring Today - MSN
Palisade Bio advances ulcerative colitis treatment - Investing.com
Palisade Bio Reports Data Demonstrating PDE4B Expression in - GlobeNewswire
Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification - Yahoo Finance
Arrowhead chases Ionis in rare, genetic disease race - BioWorld Online
Palisade Bio (NASDAQ:PALI) Trading 3.2% Higher - Defense World
Palisade Bio Edges up on Q2 Results - MSN
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome - Business Wire
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Palisade Bio Inc Azioni (PALI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Palisade Bio Inc Azioni (PALI) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Williams Donald Allen | Director |
Jun 11 '24 |
Option Exercise |
0.00 |
340 |
0 |
340 |
Jones Mitchell Lawrence | Chief Medical Officer |
May 28 '24 |
Option Exercise |
0.00 |
4,290 |
0 |
4,313 |
Finley John David | CEO, CFO, Director |
May 28 '24 |
Option Exercise |
0.00 |
7,068 |
0 |
14,079 |
Williams Donald Allen | Director |
May 28 '24 |
Buy |
4.86 |
1,000 |
4,863 |
1,000 |
Finley John David | CEO, CFO, Director |
May 24 '24 |
Buy |
4.81 |
1,000 |
4,810 |
8,437 |
Jones Mitchell Lawrence | CEO, CFO, Director |
May 06 '24 |
Option Exercise |
0.00 |
460 |
0 |
880 |
Finley John David | CEO, CFO, Director |
May 06 '24 |
Option Exercise |
0.00 |
443 |
0 |
6,832 |
Finley John David | CEO, CFO, Director |
Mar 11 '24 |
Option Exercise |
0.00 |
5,558 |
0 |
96,849 |
Neal James R | Director |
Feb 09 '24 |
Option Exercise |
0.00 |
10,920 |
0 |
10,920 |
Csimma Cristina | Director |
Feb 08 '24 |
Option Exercise |
0.00 |
12,800 |
0 |
12,862 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):